The decision means all 25 companies that produce medicines used in executions have blocked their sale for that purpose, according to Reprieve, an international human rights organiSation that opposes the death penalty.
"Pfizer's actions cement the pharmaceutical industry's opposition to the misuse of medicines," said Maya Foa, director of Reprieve, in a statement. "This will mean that all FDA-approved manufacturers of all execution drugs have spoken out against the misuse of medicines in lethal injections and taken steps to prevent it."
Pfizer's new distribution system will limit sales to specific wholesalers, distributors and direct purchasers, who must then pledge not to resell the drugs to correctional institutions for use in executions. Any government purchasing groups must certify that the medicines they buy are for their own use, for medically prescribed patient care, and won't be sold or shared with any others.
"Pfizer will consistently monitor the distribution of these seven products, act upon findings that reveal noncompliance, and modify policies when necessary to remain consistent with our stated position against the improper use of our products in lethal injections," the New York-based company said in a statement posted on its website.
The limited-distribution products are: pancuronium bromide, potassium chloride, propofol, midazolam, hydromorphone, rocuronium bromide and vecuronium bromide.
Lethal injection was the primary method of execution in the 31 states that allowed the death penalty as of July 2015, with more than 1,260 inmates dying from the practice since 1976, according to the Death Penalty Information Center.
Most lethal injections begin with an anaesthetic or a sedative, followed by pancuronium bromide, which paralyses the inmate, according to the nonprofit group. Potassium chloride is then given to stop the heart.
The number of inmates who have been put to death has declined in recent years as correctional facilities had difficulty getting the medicines used in lethal injections, activists raised concerns about the practice and stories emerged about undue suffering and bungled execution attempts. While there were three botched executions in 2014 alone, the US Supreme Court upheld the practice in a decision issued last year.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
